Skip to Main Content
Table 1.

Association between MnSOD, CAT, and GPX1 genetic polymorphisms and risk of prostate cancer

OverallCasesControlsOR (95% CI)*CasesControlsOR (95% CI)*
MnSOD       
    TT 128 (25.5) 356 (25.7) 1.0 (ref)    
    TC 258 (51.4) 683 (49.2) 1.1 (0.83-1.39)    
    CC 116 (23.1) 349 (25.1) 0.9 (0.68-1.27)    
CAT       
    CC 317 (62.4) 885 (63.1) 1.0 (ref)    
    CT 165 (32.5) 461 (32.9) 1.0 (0.77-1.22)    
    TT 26 (5.1) 57 (4.1) 1.2 (0.75-2.06)    
GPX1       
    CC 249 (49.8) 704 (50.6) 1.0 (ref)    
    CT 213 (42.6) 578 (41.6) 1.0 (0.80-1.25)    
    TT 38 (7.6) 109 (7.8) 1.0 (0.64-1.47)    
Race
 
Caucasian
 
  
 
African American
 
 
MnSOD       
    TT 112 (24.6) 293 (24.1) 1.0 (ref) 7 (25.0) 39 (32.0) 1.0 (ref) 
    TC 239 (52.5) 610 (50.3) 1.0 (0.79-1.37) 15 (53.6) 52 (42.6) 2.1 (0.67-6.31) 
    CC 104 (22.9) 311 (25.6) 0.9 (0.63-1.21) 6 (21.4) 31 (25.4) 1.3 (0.34-5.08) 
CAT       
    CC 281 (60.7) 732 (59.4) 1.0 (ref) 24 (88.9) 109 (90.8) 1.0 (ref) 
    CT 157 (33.9) 445 (36.1) 0.9 (0.71-1.15) 3 (11.1) 11 (9.2) 1.4 (0.32-6.42) 
    TT 25 (5.4) 56 (4.5) 1.1 (0.68-1.93) — — — 
GPX1       
    CC 227 (50.2) 616 (50.5) 1.0 (ref) 12 (41.4) 51 (42.9) 1.0 (ref) 
    CT 190 (40.0) 515 (42.2) 1.0 (0.77-1.23) 15 (51.7) 53 (44.5) 1.1 (0.42-2.73) 
    TT 35 (7.7) 90 (7.4) 1.1 (0.68-1.64) 2 (6.9) 15 (12.6) 0.4 (0.06-1.96) 
Randomization assignment
 
Placebo
 
  
 
Intervention
 
 
MnSOD       
    TT 52 (24.2) 148 (25.0) 1.0 (ref) 60 (25.0) 145 (23.3) 1.0 (ref) 
    TC 114 (53.0) 297 (50.2) 1.0 (0.66-1.43) 125 (52.1) 313 (50.3) 1.1 (0.75-1.66) 
    CC 49 (22.8) 147 (24.8) 0.9 (0.55-1.38) 55 (22.9) 164 (26.4) 0.9 (0.56-1.43) 
CAT       
    CC 136 (62.7) 351 (58.6) 1.0 (ref) 145 (60.1) 381 (60.1) 1.0 (ref) 
    CT 70 (32.3) 220 (36.7) 1.0 (0.73-1.42) 87 (35.4) 225 (35.5) 0.8 (0.57-1.14) 
    TT 11 (5.1) 28 (4.7) 1.2 (0.56-2.42) 14 (5.7) 28 (4.4) 1.1 (0.53-2.36) 
GPX1       
    CC 114 (52.8) 308 (51.9) 1.0 (ref) 113 (47.9) 308 (49.1) 1.0 (ref) 
    CT 81 (37.5) 237 (39.9) 1.0 (0.74-1.42) 109 (46.2) 278 (44.3) 0.9 (0.64-1.28) 
    TT 21 (9.7) 49 (8.3) 0.9 (0.47-1.87) 14 (5.9) 41 (6.5) 1.1 (0.61-1.98) 
       
 Controls
 
Cases
 
OR (95% CI)§
 
Cases
 
OR (95% CI)§
 
Age at diagnosis (y)
 
<65
 
  ≥65
 
 
MnSOD       
    TT 293 (24.1) 45 (27.0) 1.0 (ref) 67 (23.3) 1.0 (ref) 
    TC 610 (50.3) 88 (52.7) 1.0 (0.64-1.53) 151 (52.4) 1.1 (0.78-1.54) 
    CC 311 (25.6) 34 (20.3) 0.8 (0.48-1.37) 70 (24.3) 0.9 (0.63-1.41) 
CAT      
    CC 732 (59.4) 95 (54.6) 1.0 (ref) 186 (64.4) 1.0 (ref) 
    CT 445 (36.1) 66 (37.9) 1.1 (0.74-1.57) 91 (31.5) 0.8 (0.59-1.07) 
    TT 56 (4.5) 13 (7.5) 2.0 (0.97-3.95) 12 (4.2) 0.7 (0.35-1.50) 
GPX1      
    CC 616 (50.5) 90 (52.6) 1.0 (ref) 137 (48.8) 1.0 (ref) 
    CT 515 (42.2) 69 (40.4) 1.0 (0.68-1.44) 121 (43.1) 0.9 (0.71-1.27) 
    TT 90 (7.4) 12 (7.0) 1.0 (0.49-1.93) 23 (8.2) 1.1 (0.63-1.87) 
OverallCasesControlsOR (95% CI)*CasesControlsOR (95% CI)*
MnSOD       
    TT 128 (25.5) 356 (25.7) 1.0 (ref)    
    TC 258 (51.4) 683 (49.2) 1.1 (0.83-1.39)    
    CC 116 (23.1) 349 (25.1) 0.9 (0.68-1.27)    
CAT       
    CC 317 (62.4) 885 (63.1) 1.0 (ref)    
    CT 165 (32.5) 461 (32.9) 1.0 (0.77-1.22)    
    TT 26 (5.1) 57 (4.1) 1.2 (0.75-2.06)    
GPX1       
    CC 249 (49.8) 704 (50.6) 1.0 (ref)    
    CT 213 (42.6) 578 (41.6) 1.0 (0.80-1.25)    
    TT 38 (7.6) 109 (7.8) 1.0 (0.64-1.47)    
Race
 
Caucasian
 
  
 
African American
 
 
MnSOD       
    TT 112 (24.6) 293 (24.1) 1.0 (ref) 7 (25.0) 39 (32.0) 1.0 (ref) 
    TC 239 (52.5) 610 (50.3) 1.0 (0.79-1.37) 15 (53.6) 52 (42.6) 2.1 (0.67-6.31) 
    CC 104 (22.9) 311 (25.6) 0.9 (0.63-1.21) 6 (21.4) 31 (25.4) 1.3 (0.34-5.08) 
CAT       
    CC 281 (60.7) 732 (59.4) 1.0 (ref) 24 (88.9) 109 (90.8) 1.0 (ref) 
    CT 157 (33.9) 445 (36.1) 0.9 (0.71-1.15) 3 (11.1) 11 (9.2) 1.4 (0.32-6.42) 
    TT 25 (5.4) 56 (4.5) 1.1 (0.68-1.93) — — — 
GPX1       
    CC 227 (50.2) 616 (50.5) 1.0 (ref) 12 (41.4) 51 (42.9) 1.0 (ref) 
    CT 190 (40.0) 515 (42.2) 1.0 (0.77-1.23) 15 (51.7) 53 (44.5) 1.1 (0.42-2.73) 
    TT 35 (7.7) 90 (7.4) 1.1 (0.68-1.64) 2 (6.9) 15 (12.6) 0.4 (0.06-1.96) 
Randomization assignment
 
Placebo
 
  
 
Intervention
 
 
MnSOD       
    TT 52 (24.2) 148 (25.0) 1.0 (ref) 60 (25.0) 145 (23.3) 1.0 (ref) 
    TC 114 (53.0) 297 (50.2) 1.0 (0.66-1.43) 125 (52.1) 313 (50.3) 1.1 (0.75-1.66) 
    CC 49 (22.8) 147 (24.8) 0.9 (0.55-1.38) 55 (22.9) 164 (26.4) 0.9 (0.56-1.43) 
CAT       
    CC 136 (62.7) 351 (58.6) 1.0 (ref) 145 (60.1) 381 (60.1) 1.0 (ref) 
    CT 70 (32.3) 220 (36.7) 1.0 (0.73-1.42) 87 (35.4) 225 (35.5) 0.8 (0.57-1.14) 
    TT 11 (5.1) 28 (4.7) 1.2 (0.56-2.42) 14 (5.7) 28 (4.4) 1.1 (0.53-2.36) 
GPX1       
    CC 114 (52.8) 308 (51.9) 1.0 (ref) 113 (47.9) 308 (49.1) 1.0 (ref) 
    CT 81 (37.5) 237 (39.9) 1.0 (0.74-1.42) 109 (46.2) 278 (44.3) 0.9 (0.64-1.28) 
    TT 21 (9.7) 49 (8.3) 0.9 (0.47-1.87) 14 (5.9) 41 (6.5) 1.1 (0.61-1.98) 
       
 Controls
 
Cases
 
OR (95% CI)§
 
Cases
 
OR (95% CI)§
 
Age at diagnosis (y)
 
<65
 
  ≥65
 
 
MnSOD       
    TT 293 (24.1) 45 (27.0) 1.0 (ref) 67 (23.3) 1.0 (ref) 
    TC 610 (50.3) 88 (52.7) 1.0 (0.64-1.53) 151 (52.4) 1.1 (0.78-1.54) 
    CC 311 (25.6) 34 (20.3) 0.8 (0.48-1.37) 70 (24.3) 0.9 (0.63-1.41) 
CAT      
    CC 732 (59.4) 95 (54.6) 1.0 (ref) 186 (64.4) 1.0 (ref) 
    CT 445 (36.1) 66 (37.9) 1.1 (0.74-1.57) 91 (31.5) 0.8 (0.59-1.07) 
    TT 56 (4.5) 13 (7.5) 2.0 (0.97-3.95) 12 (4.2) 0.7 (0.35-1.50) 
GPX1      
    CC 616 (50.5) 90 (52.6) 1.0 (ref) 137 (48.8) 1.0 (ref) 
    CT 515 (42.2) 69 (40.4) 1.0 (0.68-1.44) 121 (43.1) 0.9 (0.71-1.27) 
    TT 90 (7.4) 12 (7.0) 1.0 (0.49-1.93) 23 (8.2) 1.1 (0.63-1.87) 
*

ORs adjusting for age at enrollment, history of prostate cancer in first-degree relative, random assignment, smoking status (current versus former or nonsmoker), pack-years smoked (<40, 40-60, ≥60), alcohol consumption (nondrinker, below median, at or above median) and vitamin supplement use in logistic regression model.

P = 0.133 for MnSOD, <0.001 for CAT, and 0.075 for GPX1 between Caucasian and African American tested by χ2 test in controls.

Restricted to Caucasians only.

§

ORs adjusting for age at enrollment, history of prostate cancer in first-degree relative, random assignment, smoking status (current versus former or nonsmoker), pack-years smoked (<40, 40-60, ≥60), alcohol consumption (nondrinker, below median, at or above median) and vitamin supplement use in polychotomous logistic regression model.

Close Modal

or Create an Account

Close Modal
Close Modal